Palisade Bio, Inc. (NASDAQ:PALI - Get Free Report) Director Robert Baltera purchased 50,000 shares of the company's stock in a transaction that occurred on Tuesday, November 17th. The stock was acquired at an average cost of $1.01 per share, with a total value of $50,500.00. Following the purchase, the director directly owned 511,904 shares of the company's stock, valued at $517,023.04. This trade represents a 10.82% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Palisade Bio Price Performance
NASDAQ:PALI traded down $0.02 during trading hours on Thursday, hitting $0.93. The company had a trading volume of 2,741,640 shares, compared to its average volume of 3,577,398. The company has a market capitalization of $165.90 million, a PE ratio of -1.93 and a beta of 1.61. The stock has a 50-day moving average price of $1.41 and a 200 day moving average price of $1.81. Palisade Bio, Inc. has a 52 week low of $0.92 and a 52 week high of $2.85.
Palisade Bio (NASDAQ:PALI - Get Free Report) last issued its quarterly earnings data on Tuesday, November 10th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.01). Analysts anticipate that Palisade Bio, Inc. will post -0.24 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of the business. Jupiter Topco LLC purchased a new stake in Palisade Bio in the second quarter worth about $22,394,000. BlackRock Inc. bought a new stake in shares of Palisade Bio in the 2nd quarter worth approximately $21,813,000. Soleus Capital Management L.P. grew its stake in shares of Palisade Bio by 14.8% in the 3rd quarter. Soleus Capital Management L.P. now owns 14,996,154 shares of the company's stock worth $20,245,000 after buying an additional 1,932,467 shares during the last quarter. Janus Henderson Group PLC grew its stake in shares of Palisade Bio by 1.4% in the 1st quarter. Janus Henderson Group PLC now owns 10,689,452 shares of the company's stock worth $18,760,000 after buying an additional 149,118 shares during the last quarter. Finally, Octagon Capital Advisors LP increased its position in Palisade Bio by 7.4% during the 1st quarter. Octagon Capital Advisors LP now owns 10,276,317 shares of the company's stock valued at $17,984,000 after buying an additional 708,419 shares in the last quarter. 11.79% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of equities analysts recently issued reports on PALI shares. Weiss Ratings reissued a "sell (e+)" rating on shares of Palisade Bio in a research note on Monday, October 12th. Wall Street Zen cut Palisade Bio from a "sell" rating to a "strong sell" rating in a research report on Saturday, November 14th. Raymond James Financial started coverage on Palisade Bio in a report on Thursday, October 8th. They set an "outperform" rating and a $6.00 target price on the stock. Oppenheimer reissued an "outperform" rating on shares of Palisade Bio in a research report on Wednesday, October 21st. Finally, HC Wainwright lowered their target price on Palisade Bio to $5.00 and set a "buy" rating for the company in a research note on Wednesday, November 11th. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $9.00.
Get Our Latest Stock Report on PALI
Palisade Bio Company Profile
(
Get Free Report)
Palisade Bio is a clinical-stage biopharmaceutical company developing therapies for gastrointestinal diseases, with a focus on oral treatments for inflammatory bowel conditions. Its pipeline includes PALI-2108, an investigational, gut-targeted PDE4 inhibitor being developed for ulcerative colitis and fibrostenotic Crohn's disease. The company has also developed LB1148, an investigational serine protease inhibitor studied for its potential to support bowel function and reduce complications after abdominal surgery.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Palisade Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Palisade Bio wasn't on the list.
While Palisade Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.